Data from large patient samples evaluating the magnitude of benefit with the newer anti-fungal agents are lacking. We have analyzed the Nationwide Inpt Sample (NIS) database to evaluate the trends in the incidence of fungal infections and to evaluate the potential impact of newer anti-fungal agents on in-hospital mortality among allo-SCT recipients. Our data suggests that the use of newer anti-fungal agents has an impact on the survivability of fungal infections in the setting of allo-SCT.